



Your Impact in Action



SUPPORTED BY



Because of your support, we have accomplished great things at Dana-Farber Cancer Institute, in just the last year:



Research

SAVING LIVES THROUGH DISCOVERY

Predicting Effectiveness of Immunotherapy

Immunotherapy, which harnesses a patient's immune system to fight cancer, is only effective for a small proportion of patients. In multiple studies at Dana-Farber, researchers have identified biomarkers that can help predict which patients will benefit from immunotherapy, to make these treatments more effective.

Hope for Neuroblastoma

Using CRISPR technology, Dana-Farber researchers muted one gene at a time to reveal a protein target in neuroblastoma—the most common cancer in infants—which appears to be vulnerable to newly developed drugs, setting the stage for clinical trials.

Identifying Epigenetic Drivers

Mutant genes can cause cancer, but so can normal genes when they are activated at the wrong time. Studying epigenetic factors that control gene regulation, Dana-Farber researchers have uncovered how gene regulators known as BAF complexes are "hijacked" to cause prostate cancer, among others.

Improving Survival in Colon Cancer

In a large study of non-metastatic colon cancer patients, Dana-Farber researchers confirmed that those who followed a diet low in carbohydrates and other foods that raise insulin levels can sharply reduce their risk of recurrence, offering patients a powerful tool to improve prospects of survival.

Treatment for GVHD

Dana-Farber researchers, who pioneered the use of the immune signaling protein interleukin-2 (IL-2) in post-transplant patients, showed in multiple studies that daily low doses of IL-2 can safely benefit patients, including children, who develop chronic graft-versus-host disease following stem cell transplants.

Overcoming Resistance in Breast Cancer

A majority of breast cancers are fueled by the hormone estrogen, and treatment resistance in estrogen receptor-positive breast cancer is an ongoing challenge. Now Dana-Farber researchers have identified a cause of resistance and metastasis in such cancers and experimental agents with the potential to overcome them.



Your Impact in Action

 DANA-FARBER
CANCER INSTITUTE

SUPPORTED BY
 The Jimmy Fund®



Patient Care

PREVENTION, DETECTION, AND TREATMENT

Genetic Screening for Pancreatic Cancer

A large Dana-Farber study of pancreatic cancer patients revealed that almost 10 percent harbored inherited genetic variations that may have increased their susceptibility to the disease, prompting our physicians to recommend genetic testing for all pancreatic cancer patients at the time of diagnosis, regardless of their age or family history of cancer.

Expanded Lab Fuels Precision Patient Care

The Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber, which supports more than 600 stem cell transplants, 40 clinical trials, and personalized treatments such as CAR T-cell therapy, tripled in size this year, becoming one of the largest in an academic center in the world.

Precision Medicine for Thyroid Cancer

Dana-Farber launched Thyroid Cancer 360, a precision medicine program specializing in targeted treatments for patients with advanced and aggressive thyroid cancers. Research from patient profiles will help to advance diagnostic and treatment strategies.

Enhancing Access to Care

To help make high-quality cancer care available to more patients, Dana-Farber launched a Chinese-language website, and doubled the size of the cancer clinic it maintains in Haiti with Partners in Health.



Honors

RECOGNITION AND RANKINGS

Number 1 in New England

In 2018, Dana-Farber Cancer Institute was the top ranked cancer hospital in New England by U.S. News and World Report for the 18th consecutive year, and was once again the only cancer center in the country ranked in the top 4 for both adult and pediatric cancer programs.

Welcoming to All

In recognition of our efforts to provide a welcoming, inclusive, and affirming environment for all patients, as well as for faculty and staff, Dana-Farber was named an LGBTQ Healthcare Equality Leader by the Human Rights Campaign Foundation for the 10th time since 2008.

A Leader in Prevention

Tobacco Free Mass, a coalition that has advocated for funding and policies supporting tobacco prevention and cessation for 25 years, recognized Dana-Farber for "continued leadership in the fight against tobacco and its harms."

Highest Quality Care

In *Boston* magazine's Top Doctors Guide, 115 physicians and surgeons affiliated with Dana-Farber Cancer Institute were recognized for their compassionate, expert care.



"Your remarkable generosity has enabled us to push the pace of scientific progress and deliver exceptional patient care. Thank you for the vital role you play in our lifesaving mission."

Laurie H. Glimcher, MD
President and CEO
Dana-Farber Cancer Institute



Find out more: Dana-Farber.org | JimmyFund.org